View Past PerformanceCell Source バランスシートの健全性財務の健全性 基準チェック /06Cell Sourceの総株主資本は$-20.1M 、総負債は$10.8Mで、負債比率は-53.7%となります。総資産と総負債はそれぞれ$292.4Kと$20.4Mです。主要情報-53.72%負債資本比率US$10.82m負債インタレスト・カバレッジ・レシオn/a現金US$1.24kエクイティ-US$20.14m負債合計US$20.43m総資産US$292.45k財務の健全性に関する最新情報お知らせ • Mar 29Cell Source, Inc. announced delayed annual 10-K filingOn 03/28/2025, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 15Cell Source, Inc. announced delayed 10-Q filingOn 08/14/2024, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Cell Source, Inc. announced delayed annual 10-K filingOn 04/01/2024, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 17Cell Source, Inc. announced delayed 10-Q filingOn 08/15/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Cell Source, Inc. announced delayed 10-Q filingOn 05/16/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 13Cell Source, Inc. announced delayed 10-Q filingOn 05/12/2022, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.すべての更新を表示Recent updatesお知らせ • Mar 29Cell Source, Inc. announced delayed annual 10-K filingOn 03/28/2025, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 21Cell Source, Inc. Shared Positive Interim Results from Its Phase 1/2 First-In-Human Clinical Trial Conducted At the University of Texas Md Anderson Cancer CenterCell Source, Inc. shared positive interim results from its Phase 1/2 First-in-Human clinical trial conducted at The University of Texas MD Anderson Cancer Center. The trial has treated 15 patients using Cell Source's proprietary Veto Cell technology in stem cell transplants for malignant and non-malignant hematologic diseases. These early results indicate both safety and efficacy, marking a promising advance in stem cell transplant outcomes. Breakthrough Results for Safer and Effective Transplants Previously presented at the American Society for Hematology (ASH) Annual Meeting, the interim study results highlight: Consistent engraftment without severe GvHD: Achieved at 42 days post- transplant with T-cell-depleted, haploidentical stem cell transplants under reduced intensity conditioning (RIC).No toxicity linked to Veto Cells: No patients experienced adverse effects directly associated with Veto Cells. Enhanced protocol: A mild conditioning regimen, combined with Rituximab to prevent antibody-related complications, makes transplants safer and suitable for a broader range of patients. These findings underscore the potential of Veto Cells to increase access to life-saving allogeneic transplants for cancer patients and individuals with non-malignant blood disorders, supporting the strategic advancement of Cell Source's technology. Comparable Successes Demonstrate Market Potential The cell therapy and immunotherapy market has seen robust investor interest, with several start-up companies achieving multibillion-dollar valuations after clinical success. For example, Kite Pharma and Juno Therapeutics were acquired for $12 billion and $9 billion, respectively, following successful clinical outcomes and regulatory approvals in similar areas of cellular therapy. These precedents highlight the significant financial upside for novel treatments that achieve distinctive clinical efficacy and regulatory milestones. With Cell Source's Veto Cell platform showing early promise in achieving safer and thus more effective stem cell transplants without severe GvHD, the Company is strategically positioned to capitalize on this expanding market. The total addressable market (TAM) for hematological therapeutics, including both cancer and nonmalignant diseases, is estimated to be in excess of $100 billion, underscoring the vast commercial potential for Veto Cells to gain market traction as the platform advances through clinical trials. Pathway to Market and Competitive EdgeCell Source's Veto Cell technology offers a unique advantage by combining reduced immune suppression with avoidance to GvHD, making it an attractive alternative to current stem cell transplant methods. The Company's Veto Cell platform is also being developed for organ transplant applications, potentially allowing for partially mismatched donors as well as reducing or possibly even eliminating reliance on lifelong immunosuppression post-transplant.お知らせ • Aug 15Cell Source, Inc. announced delayed 10-Q filingOn 08/14/2024, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Cell Source, Inc. announced delayed annual 10-K filingOn 04/01/2024, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 17Cell Source, Inc. announced delayed 10-Q filingOn 08/15/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.New Risk • Jun 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.9m free cash flow). Shares are highly illiquid. Negative equity (-US$12m). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$14.9k market cap). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Shareholders have been diluted in the past year (8.0% increase in shares outstanding).お知らせ • May 17Cell Source, Inc. announced delayed 10-Q filingOn 05/16/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jul 22Cell Source, Inc. Announces Board ResignationsCell Source, Inc. announced that onJuly 18, 2022, each of Ben Friedman and David Zolty resigned his position as a director of the company.お知らせ • May 13Cell Source, Inc. announced delayed 10-Q filingOn 05/12/2022, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01Cell Source, Inc. announced delayed annual 10-K filingOn 03/31/2022, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Mar 21USPTO Issues New Patents for Cell Source's Veto Cell TechnologyCell Source, Inc. announced that it has received USPTO issuance notices for two patents covering its Veto Cell technology. The first patent, "Veto Cells Generated from Memory T Cells", describes Veto Cells that safely elicit patient acceptance of transplanted cells, such as stem cells, by overcoming the barriers of graft rejection and graft versus host disease (GvHD). Veto Cells are also capable of fighting potential viral and bacterial infections and can treat unresponsive cancers or cancers where limited treatment options exist. The second patent, "Methods of Transplantation and Disease Treatment", describes an invention in which Veto Cells act as unique, powerful companion cells that allow cellular therapies such as CAR-T and NK to be safely tolerated by the patient without transplant rejection or graft vs. host disease (GvHD) – while increasing overall combined treatment impact. The patents describe Veto Cell inventions in which Veto Cells work in conjunction with existing stem cell transplant therapies to protect the patient from transplant-related complications while increasing overall treatment efficacy, as well as inventions in which Veto Cells have been exposed to third-party antigens, thereby enabling Veto Cells to work on their own to effectively target cancers that have not responded to genetically modified T-cell therapies or where these therapies do not currently exist.お知らせ • Mar 14Cell Source, Inc. Announces its Veto T-Cell Bone Marrow Transplant Safely Demonstrates Potential Cure for Sickle Cell Anemia in Preclinical TrialsCell Source, Inc. announced that its fully mismatched mouse Veto Cell based BMT protocol has overcome significant challenges to durably prevent the onset of the pathological parameters of sickle cell disease (SCD) including complete conversion to normal, donor-derived red blood cells. The study, correction of murine sickle cell disease by allogeneic hæmatopoietic cell transplantation with anti-3rd party veto cells, published online by BMT Journalon March 3, 2021. As noted in BMT Journal, the Veto Cell protocol was able to safely and efficaciously achieve durable, donor-derived chimerism in mice prone to sickle cell disease (i.e., the donor's transplanted healthy cells begin to be produced by the recipient mice instead of the host defective cells) and prevent onset of SCD pathology by overcoming several significant challenges, including: the need for safer partially or fully mismatched bone marrow transplantation (BMT) protocols; the challenge of transplant rejection under reduced intensity conditioning (RIC); and the possibility of graft vs. host disease under RIC. A phase 1/2 clinical trial is currently in progress testing the safety and efficacy of the company’s Veto Cells in patients with hematological cancers or with non-malignant hematological diseases including SCD.お知らせ • Feb 26Cell Source, Inc. Appoints Joseph Rosenthal to Scientific Advisory BoardCell Source, Inc. announced that Joseph Rosenthal has joined its Scientific Advisory Board. Dr. Rosenthal is currently the Director of Pediatric Hematology-Oncology and Barron Hilton Professor & Chair in Pediatrics at City of Hope National Medical Center in Duarte, CA.財務状況分析短期負債: CLCSは マイナスの株主資本 を有しており、これは 短期資産 が 短期負債 をカバーしていないことよりも深刻な状況です。長期負債: CLCSは株主資本がマイナスであり、これは短期資産が 長期負債 をカバーしていないことよりも深刻な状況です。デット・ツー・エクイティの歴史と分析負債レベル: CLCSは 株主資本がマイナス となっており、これは高い負債レベルよりも深刻な状況です。負債の削減: CLCSの株主資本はマイナスなので、時間の経過とともに負債が減少したかどうかを確認する必要はありません。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: 現在のフリーキャッシュフローに基づいて、 CLCSに十分なキャッシュランウェイがあるかどうかを判断するにはデータが不十分です。キャッシュランウェイの予測: CLCSの フリー キャッシュ フロー が過去のレートに基づいて増加または減少し続ける場合、十分な キャッシュ ランウェイ があるかどうかを判断するためのデータが不十分です。健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/08 05:04終値2026/06/08 00:00収益2025/03/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cell Source, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 29Cell Source, Inc. announced delayed annual 10-K filingOn 03/28/2025, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 15Cell Source, Inc. announced delayed 10-Q filingOn 08/14/2024, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Cell Source, Inc. announced delayed annual 10-K filingOn 04/01/2024, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 17Cell Source, Inc. announced delayed 10-Q filingOn 08/15/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Cell Source, Inc. announced delayed 10-Q filingOn 05/16/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 13Cell Source, Inc. announced delayed 10-Q filingOn 05/12/2022, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Mar 29Cell Source, Inc. announced delayed annual 10-K filingOn 03/28/2025, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 21Cell Source, Inc. Shared Positive Interim Results from Its Phase 1/2 First-In-Human Clinical Trial Conducted At the University of Texas Md Anderson Cancer CenterCell Source, Inc. shared positive interim results from its Phase 1/2 First-in-Human clinical trial conducted at The University of Texas MD Anderson Cancer Center. The trial has treated 15 patients using Cell Source's proprietary Veto Cell technology in stem cell transplants for malignant and non-malignant hematologic diseases. These early results indicate both safety and efficacy, marking a promising advance in stem cell transplant outcomes. Breakthrough Results for Safer and Effective Transplants Previously presented at the American Society for Hematology (ASH) Annual Meeting, the interim study results highlight: Consistent engraftment without severe GvHD: Achieved at 42 days post- transplant with T-cell-depleted, haploidentical stem cell transplants under reduced intensity conditioning (RIC).No toxicity linked to Veto Cells: No patients experienced adverse effects directly associated with Veto Cells. Enhanced protocol: A mild conditioning regimen, combined with Rituximab to prevent antibody-related complications, makes transplants safer and suitable for a broader range of patients. These findings underscore the potential of Veto Cells to increase access to life-saving allogeneic transplants for cancer patients and individuals with non-malignant blood disorders, supporting the strategic advancement of Cell Source's technology. Comparable Successes Demonstrate Market Potential The cell therapy and immunotherapy market has seen robust investor interest, with several start-up companies achieving multibillion-dollar valuations after clinical success. For example, Kite Pharma and Juno Therapeutics were acquired for $12 billion and $9 billion, respectively, following successful clinical outcomes and regulatory approvals in similar areas of cellular therapy. These precedents highlight the significant financial upside for novel treatments that achieve distinctive clinical efficacy and regulatory milestones. With Cell Source's Veto Cell platform showing early promise in achieving safer and thus more effective stem cell transplants without severe GvHD, the Company is strategically positioned to capitalize on this expanding market. The total addressable market (TAM) for hematological therapeutics, including both cancer and nonmalignant diseases, is estimated to be in excess of $100 billion, underscoring the vast commercial potential for Veto Cells to gain market traction as the platform advances through clinical trials. Pathway to Market and Competitive EdgeCell Source's Veto Cell technology offers a unique advantage by combining reduced immune suppression with avoidance to GvHD, making it an attractive alternative to current stem cell transplant methods. The Company's Veto Cell platform is also being developed for organ transplant applications, potentially allowing for partially mismatched donors as well as reducing or possibly even eliminating reliance on lifelong immunosuppression post-transplant.
お知らせ • Aug 15Cell Source, Inc. announced delayed 10-Q filingOn 08/14/2024, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Cell Source, Inc. announced delayed annual 10-K filingOn 04/01/2024, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 17Cell Source, Inc. announced delayed 10-Q filingOn 08/15/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
New Risk • Jun 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.9m free cash flow). Shares are highly illiquid. Negative equity (-US$12m). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$14.9k market cap). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Shareholders have been diluted in the past year (8.0% increase in shares outstanding).
お知らせ • May 17Cell Source, Inc. announced delayed 10-Q filingOn 05/16/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jul 22Cell Source, Inc. Announces Board ResignationsCell Source, Inc. announced that onJuly 18, 2022, each of Ben Friedman and David Zolty resigned his position as a director of the company.
お知らせ • May 13Cell Source, Inc. announced delayed 10-Q filingOn 05/12/2022, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01Cell Source, Inc. announced delayed annual 10-K filingOn 03/31/2022, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Mar 21USPTO Issues New Patents for Cell Source's Veto Cell TechnologyCell Source, Inc. announced that it has received USPTO issuance notices for two patents covering its Veto Cell technology. The first patent, "Veto Cells Generated from Memory T Cells", describes Veto Cells that safely elicit patient acceptance of transplanted cells, such as stem cells, by overcoming the barriers of graft rejection and graft versus host disease (GvHD). Veto Cells are also capable of fighting potential viral and bacterial infections and can treat unresponsive cancers or cancers where limited treatment options exist. The second patent, "Methods of Transplantation and Disease Treatment", describes an invention in which Veto Cells act as unique, powerful companion cells that allow cellular therapies such as CAR-T and NK to be safely tolerated by the patient without transplant rejection or graft vs. host disease (GvHD) – while increasing overall combined treatment impact. The patents describe Veto Cell inventions in which Veto Cells work in conjunction with existing stem cell transplant therapies to protect the patient from transplant-related complications while increasing overall treatment efficacy, as well as inventions in which Veto Cells have been exposed to third-party antigens, thereby enabling Veto Cells to work on their own to effectively target cancers that have not responded to genetically modified T-cell therapies or where these therapies do not currently exist.
お知らせ • Mar 14Cell Source, Inc. Announces its Veto T-Cell Bone Marrow Transplant Safely Demonstrates Potential Cure for Sickle Cell Anemia in Preclinical TrialsCell Source, Inc. announced that its fully mismatched mouse Veto Cell based BMT protocol has overcome significant challenges to durably prevent the onset of the pathological parameters of sickle cell disease (SCD) including complete conversion to normal, donor-derived red blood cells. The study, correction of murine sickle cell disease by allogeneic hæmatopoietic cell transplantation with anti-3rd party veto cells, published online by BMT Journalon March 3, 2021. As noted in BMT Journal, the Veto Cell protocol was able to safely and efficaciously achieve durable, donor-derived chimerism in mice prone to sickle cell disease (i.e., the donor's transplanted healthy cells begin to be produced by the recipient mice instead of the host defective cells) and prevent onset of SCD pathology by overcoming several significant challenges, including: the need for safer partially or fully mismatched bone marrow transplantation (BMT) protocols; the challenge of transplant rejection under reduced intensity conditioning (RIC); and the possibility of graft vs. host disease under RIC. A phase 1/2 clinical trial is currently in progress testing the safety and efficacy of the company’s Veto Cells in patients with hematological cancers or with non-malignant hematological diseases including SCD.
お知らせ • Feb 26Cell Source, Inc. Appoints Joseph Rosenthal to Scientific Advisory BoardCell Source, Inc. announced that Joseph Rosenthal has joined its Scientific Advisory Board. Dr. Rosenthal is currently the Director of Pediatric Hematology-Oncology and Barron Hilton Professor & Chair in Pediatrics at City of Hope National Medical Center in Duarte, CA.